{"organizations": [], "uuid": "5e70ffbc218aaa2dd81d353a08bf8272e6623ade", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://si.wsj.net/public/resources/images/BN-WW859_CELGEN_SOC_20180108132654.jpg", "site_section": "https://www.wsj.com/news/markets", "section_title": "Stock Market &amp; Finance News - Wall Street Journal", "url": "https://www.wsj.com/articles/celgene-cant-cure-the-biotech-blues-1515435381", "country": "US", "domain_rank": 387, "title": "Celgene Can’t Cure the Biotech Blues", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.009, "site_type": "news", "published": "2018-01-08T21:16:00.000+02:00", "replies_count": 0, "uuid": "5e70ffbc218aaa2dd81d353a08bf8272e6623ade"}, "author": "Charley Grant", "url": "https://www.wsj.com/articles/celgene-cant-cure-the-biotech-blues-1515435381", "ord_in_thread": 0, "title": "Celgene Can’t Cure the Biotech Blues", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "celgene", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Good news isn’t helping a key biotech bellwether turn its fortunes around. That suggests a gloomy year for the sector.\nCelgene, one of the world’s largest biotech companies, announced Monday it expects sales of about $14.6 billion and adjusted earnings of about $8.80 a share in 2018. That’s in line with analyst expectations. But Celgene—and the sector—traded lower on Monday.\nCelgene... ", "external_links": [], "published": "2018-01-08T21:16:00.000+02:00", "crawled": "2018-01-08T21:43:04.022+02:00", "highlightTitle": ""}